EXOSLA LIMITED
Company number 12540839 · Monitor this company
Free AI analysis
Have an AI read this company's filings and write an assessment — financial health, risks, and what the numbers say.
Shareholders' funds
-£67,269
Balance sheet as at 2025-03-31
Overview
- Company type
- Private Limited Company
- Incorporated
- 2020-03-31
- Employees
- 2 (2025 accounts)
- Registered office
- 181 Cambridge Science Park, Cambridge, Cambridgeshire, United Kingdom, CB4 0GJ
- Postcode
- CB4 0GJ
- Capital
- 1 GBP
- Accounts category
- Total Exemption Full
Accounts
- Last made up to
- 2025-03-31
- Next due by
- 2026-12-31
- Financial year end
- 31 March
Confirmation statement
- Last statement dated
- 2025-06-04
- Next due by
- 2026-06-18
Nature of business (SIC)
- 72110 Research and experimental development on biotechnology
Officers 2 current · 1 resigned
Contact details
- Website
- exosla.com
Your browser does not support HTML5 video. Greatly improving neurological outcomes for newborn infants Pioneering immune-modulatory, off-the-shelf restorative medicine Science Multimodal signalling approaches are the future of immunotherapy, ranging from autoimmunity to tissue repair. However, they have been hindered by various scientific and manufacturing challenges, such as lack of adequate quality control and batch-to-batch
Competitors Cambridge
This company ranks 198 among research and experimental development on biotechnology in Cambridge.
The class of 2020
41%
of the 595 companies in this sector incorporated in 2020 are still active today; 55% have since been dissolved.
A fact about the year, not a forecast for this company.